Y. Takano

A novel and selective sodium‐glucose cotransporter‐2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus

Shuta Ikeda, Y. Takano, Osamu Cynshi et al. · Diabetes Obesity and Metabolism · 2015 · 71 citations

Pharmacokinetics and Pharmacodynamics of Tofogliflozin (a Selective SGLT2 Inhibitor) in Healthy Male Subjects

Nahoko Kasahara-Ito, Hiroyuki Fukase, Yoichiro Ogama et al. · Drug Research · 2017 · 39 citations

Impairment of Absorption of Digoxin by Acarbose

Takanori Miura, Kazuyuki Ueno, Kazuhiko Tanaka et al. · The Journal of Clinical Pharmacology · 1998 · 31 citations

A Pharmacokinetic/Pharmacodynamic Drug–Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs

Nobuo Kasahara, Hiroyuki Fukase, Yasuhiro Ohba et al. · Drug Research · 2015 · 12 citations

Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Tofogliflozin (A SELECTIVE SGLT2 Inhibitor) in Patients with Type 2 Diabetes Mellitus

Sachiya Ikeda, Y. Takano, Dietmar Schwab et al. · Drug Research · 2018 · 12 citations